Plain-English translation of NCT05878769 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a follow-up study for people with chronic obstructive pulmonary disease (COPD) who finished an earlier trial of , a new medication designed to help manage this condition. In this phase, eligible participants will continue receiving the medication by injection every two weeks, and researchers will monitor its long-term safety and how well it works over time.
While earlier trials showed the medication was effective over 52 weeks, doctors need to understand how safe and beneficial this treatment remains when people use it for much longer. This study helps answer that important question.
If you qualify, you will continue visiting the research clinic regularly to receive injections of the medication under your skin every two weeks. The study will continue until it is completed, during which time researchers will monitor your health through routine visits and tests to ensure the medication remains safe and is helping your lung disease. You'll work closely with the research team to track any changes in your symptoms or health.
AI-generated summary from trial data · Aug 30, 2026 · Not medical advice
United States